Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabelecleucel for EBV-associated Malignancies
NCT01498484Phase 2Completed
- Sponsor
- Atara Biotherapeutics
- Start
- Dec 2011
- Primary completion
- Jul 2019
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tabelecleucel in Post-Transplant Lymphoproliferative Disorder (PTLD), lymphoproliferative disorders (LPD), leiomyosarcoma (LMS), nasopharyngeal carcinoma (NPC), lymphoma, sponsored by Atara Biotherapeutics. Started Dec 2011; status: completed.
02
Drugs
tabelecleucel
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)lymphoproliferative disorders (LPD)leiomyosarcoma (LMS)nasopharyngeal carcinoma (NPC)lymphoma
Beyond the preview
Go deeper on NCT01498484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01498484.